This review evaluates finerenone's impact on chronic kidney disease and cardiovascular outcomes in type 2 diabetes, highlighting its anti-inflammatory benefits.
Key Points
Finerenone significantly reduces inflammation and fibrosis in patients with type 2 diabetes mellitus.
It acts as a selective mineralocorticoid receptor antagonist, providing cardioprotective effects over traditional treatments.
The review synthesizes clinical trial results and demonstrates finerenone's positive outcomes on cardiovascular and renal health.
Targeting mineralocorticoid receptors is essential for mitigating damage from chronic kidney disease and heart failure.